Design, synthesis, and evaluation of cyclic C7-bridged monocarbonyl curcumin analogs containing an o-methoxy phenyl group as potential agents against gastric cancer

References

• Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):1–14.
   PubMed Web of Science ®Google Scholar
• Li Q, Chen L, Dong Z, Zhao Y, Deng H, Wu J, Wu X, Li W. Piperlongumine analogue L50377 induces pyroptosis via ROS mediated NF-κB suppression in non-small-cell lung cancer. Chem Biol Interact. 2019;313:108820.
   PubMed Web of Science ®Google Scholar
• Newman DJ, Cragg GM. Natural products as sources of new drugs from 1981 to 2014. J Nat Prod. 2016;79(3):629–661.
   PubMed Web of Science ®Google Scholar
• Rodrigues FC, Kumar NA, Thakur G. The potency of heterocyclic curcumin analogues: an evidence-based review. Pharmacol Res. 2021;166:105489.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang C, Ren Z, Zhang F, Xu J, Zhang X, Zheng H. Curcumin affects gastric cancer cell migration, invasion and cytoskeletal remodeling through Gli1-β-catenin. Cancer Manag Res. 2020;12:3795–3806.
   PubMed Web of Science ®Google Scholar
• Liang T, Zhang X, Xue W, Zhao S, Zhang X, Pei J. Curcumin induced human gastric cancer BGC-823 cells apoptosis by ROS-mediated ASK1-MKK4-JNK stress signaling pathway. Int J Mol Sci. 2014;15(9):15754–15765.
   PubMed Web of Science ®Google Scholar
• Cai XZ, Wang J, Li XD, Wang GL, Liu FN, Cheng MS, Li F. Curcumin suppresses proliferation and invasion in human gastric cancer cells by downregulation of PAK1 activity and cyclin D1 expression. Cancer Biol Ther. 2009;8(14):1360–1368.
   PubMed Web of Science ®Google Scholar
• Chen QH. Curcumin-based anti-prostate cancer agents. Anticancer Agents Med Chem. 2015;15(2):138–156.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang R, Perez GR, Chen G, Zhang Q, Zheng S, Wang G, Chen QH. Design, synthesis, and biological evaluation of 1,9-diheteroarylnona-1,3,6,8-tetraen-5-ones as a new class of anti-prostate cancer agents. Bioorg Med Chem. 2016;24(19):4692–4700.
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang X, Chen C, Chen G, Zhong Q, Zhang Q, Zheng S, Wang G, Chen QH. Synthesis and evaluation of 1,7-diheteroarylhepta-1,4,6-trien-3-ones as curcumin-based anticancer agents. Eur J Med Chem. 2016;110:164–180.
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang X, Chen C, Chen G, Sarabia C, Zhang Q, Zheng S, Wang G, Chen QH. Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models. Eur J Med Chem. 2017;133:208–226.
   PubMed Web of Science ®Google Scholar
• Chuprajob T, Changtam C, Chokchaisiri R, Chunglok W, Sornkaew N, Suksamrarn A. Synthesis, cytotoxicity against human oral cancer KB cells and structure-activity relationship studies of trienone analogues of curcuminoids. Bioorg Med Chem Lett. 2014;24(13):2839–2844.
   PubMed Web of Science ®Google Scholar
• Ying S, Du X, Fu W, Yun D, Chen L, Cai Y, Xu Q, Wu J, Li W, Liang G. Synthesis, biological evaluation, QSAR and molecular dynamics simulation studies of potential fibroblast growth factor receptor 1 inhibitors for the treatment of gastric cancer. Eur J Med Chem. 2017;127:885–899.
   PubMed Web of Science ®Google Scholar
• Huang L, Wang J, Chen L, Zhu M, Wu S, Chu S, Zheng Y, Fan Z, Zhang J, Li W, et al. Design, synthesis, and evaluation of NDGA analogues as potential anti-ischemic stroke agents. Eur J Med Chem. 2018;143:1165–1173.
   PubMedGoogle Scholar
• Li G, Zheng Y, Yao J, Hu L, Liu Q, Ke F, Feng W, Zhao Y, Yan P, He W, et al. Design and green synthesis of piperlongumine analogs and their antioxidant activity against cerebral ischemia-reperfusion injury. ACS Chem Neurosci. 2019;10(11):4545–4557.
   PubMed Web of Science ®Google Scholar
• Xu S, Chen M, Chen W, Hui J, Ji J, Hu S, Zhou J, Wang Y, Liang G. Chemopreventive effect of chalcone derivative, L2H17, in colon cancer development. BMC Cancer. 2015;15(1):870.
   PubMedGoogle Scholar
• Xiao J, Wang Y, Peng J, Guo L, Hu J, Cao M, Zhang X, Zhang H, Wang Z, Li X, et al. A synthetic compound, 1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one (B63), induces apoptosis and activates endoplasmic reticulum stress in non-small cell lung cancer cells. Int J Cancer. 2012;131(6):1455–1465.
   PubMed Web of Science ®Google Scholar
• Chen X, Chen X, Zhang X, Wang L, Cao P, Rajamanickam V, Wu C, Zhou H, Cai Y, Liang G, et al. Curcuminoid B63 induces ROS-mediated paraptosis-like cell death by targeting TrxR1 in gastric cells. Redox Biol. 2019;21:101061.
   PubMed Web of Science ®Google Scholar
• Khwaja S, Fatima K, Hasanain M, Behera C, Kour A, Singh A, Luqman S, Sarkar J, Chanda D, Shanker K, et al. Antiproliferative efficacy of curcumin mimics through microtubule destabilization. Eur J Med Chem. 2018;151:51–61.
   PubMed Web of Science ®Google Scholar
• Burden FR. Quantitative structure–activity relationship studies using Gaussian processes. J Chem Inf Comput Sci. 2001;41(3):830–835.
   PubMedGoogle Scholar
• Wang J, Yun D, Yao J, Fu W, Huang F, Chen L, Wei T, Yu C, Xu H, Zhou X, et al. Design, synthesis and QSAR study of novel isatin analogues inspired Michael acceptor as potential anticancer compounds. Eur J Med Chem. 2018;144:493–503.
   PubMed Web of Science ®Google Scholar
• Svetnik V, Liaw A, Tong C, Culberson JC, Sheridan RP, Feuston BP. Random forest: a classification and regression tool for compound classification and QSAR modeling. J Chem Inf Comput Sci. 2003;43(6):1947–1958.
   PubMedGoogle Scholar
• Gong G, Guan YY, Zhang ZL, Rahman K, Wang SJ, Zhou S, Luan X, Zhang H. Isorhamnetin: a review of pharmacological effects. Biomed Pharmacother. 2020;128:110301.
   PubMed Web of Science ®Google Scholar
• Camini FC, Costa DC. Silymarin: not just another antioxidant. J Basic Clin Physiol Pharmacol. 2020;31(4):20190206.
   Google Scholar
• Qiu P, Zhang S, Zhou Y, Zhu M, Kang Y, Chen D, Wang J, Zhou P, Li W, Xu Q, et al. Synthesis and evaluation of asymmetric curcuminoid analogs as potential anticancer agents that downregulate NF-κB activation and enhance the sensitivity of gastric cancer cell lines to irinotecan chemotherapy. Eur J Med Chem. 2017;139:917–925.
   PubMed Web of Science ®Google Scholar
• Wu J, Wang C, Cai Y, Yang S, Zheng X, Qiu P, Peng J, Wu X, Liang G, Li X. Synthesis, crystal structure, antibacterial and anti-tumor properties of mono-carbonyl analogues of curcumin. Chin J Org Chem. 2010;30(6):884–889.
   Web of Science ®Google Scholar
• Chen X, Huang Y, Liu J, Lin W, Chen C, Chen Y, Ding Y, Yang Y, Chen Y, Wang H, et al. EXOSC5 promotes proliferation of gastric cancer through regulating AKT/STAT3 signaling pathways. J Cancer. 2022;13(5):1456–1467.
   PubMed Web of Science ®Google Scholar
• Lin S, Que Y, Que C, Li F, Deng M, Xu D. Exosome miR-3184-5p inhibits gastric cancer growth by targeting XBP1 to regulate the AKT, STAT3, and IRE1 signalling pathways. Asia-Pac J Clin Oncol. 2023;19(1):e27–e38.
   PubMedGoogle Scholar
• Wu J, Wu S, Shi L, Zhang S, Ren J, Yao S, Yun D, Huang L, Wang J, Li W, et al. Design, synthesis, and evaluation of asymmetric EF24 analogues as potential anti-cancer agents for lung cancer. Eur J Med Chem. 2017;125:1321–1331.
   PubMed Web of Science ®Google Scholar
• Russo A, Li P, Strong VE. Differences in the multimodal treatment of gastric cancer: east versus west. J Surg Oncol. 2017;115(5):603–614.
   PubMed Web of Science ®Google Scholar
• Dikken JL, van de Velde CJ, Coit DG, Shah MA, Verheij M, Cats A. Treatment of resectable gastric cancer. Therap Adv Gastroenterol. 2012;5(1):49–69.
   PubMed Web of Science ®Google Scholar
• Garrido M, Fonseca PJ, Vieitez JM, Frunza M, Lacave AJ. Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer. Expert Rev Anticancer Ther. 2014;14(8):887–900.
   PubMed Web of Science ®Google Scholar
• Jin R, Xia Y, Chen Q, Li W, Chen D, Ye H, Zhao C, Du X, Shi D, Wu J, et al. Da0324, an inhibitor of nuclear factor-κB activation, demonstrates selective antitumor activity on human gastric cancer cells. Drug Des Devel Ther. 2016;10:979–995.
   PubMed Web of Science ®Google Scholar
• Xia Y, Weng B, Wang Z, Kang Y, Shi L, Huang G, Ying S, Du X, Chen Q, Jin R, et al. W346 inhibits cell growth, invasion, induces cycle arrest and potentiates apoptosis in human gastric cancer cells in vitro through the NF-κB signaling pathway. Tumour Biol. 2016;37(4):4791–4801.
   PubMedGoogle Scholar
• Von Hoff DD, Weisenthal LM, Ihde DC, Mathews MJ, Layard M, Makuch R. Growth of lung cancer colonies from bronchoscopy washings. Cancer. 1981;48(2):400–403.
   PubMed Web of Science ®Google Scholar
• Koren E, Fuchs Y. Modes of Regulated Cell Death in Cancer. Cancer Discov. 2021;11(2):245–265.
   PubMed Web of Science ®Google Scholar
• Chen L, Li Q, Weng B, Wang J, Zhou Y, Cheng D, Sirirak T, Qiu P, Wu J. Design, synthesis, anti-lung cancer activity, and chemosensitization of tumor-selective MCACs based on ROS-mediated JNK pathway activation and NF-κB pathway inhibition. Eur J Med Chem. 2018;151:508–519.
   PubMed Web of Science ®Google Scholar